文献速递呼吸道感染呼吸危重症与机械通气

血液系统恶性肿瘤合并急性呼吸衰竭患者肺孢子菌肺炎的多变量预测模型

A Multivariable Prediction Model for Pneumocystis jirovecii Pneumonia in Hematology Patients with Acute Respiratory Failure.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

本研究基于前瞻性多中心队列开发并验证了血液系统恶性肿瘤合并急性呼吸衰竭ICU患者的肺孢子菌肺炎(PjP)多变量风险预测模型。模型纳入年龄、淋巴增殖性疾病、抗肺孢子菌预防、呼吸症状至ICU入住天数、休克、胸片模式及胸腔积液,推导队列AUC 0.80(95%CI 0.76-0.84),验证队列AUC 0.83(95%CI 0.72-0.93);验证队列最佳阈值3时敏感度86.7%、特异度67.7%,10%患病率下阴性预测值97.9%。

要点

  • 模型可在入院时基于易得变量计算,用于识别PjP低风险患者。
  • 验证队列阈值3时敏感度86.7%、特异度67.7%,10%患病率下阴性预测值97.9%。
  • 推导队列PjP发生率12.3%(95%CI 10.4-14.4%),验证队列6.3%(95%CI 3.6-10.2%)。

核心结论

  • 该PjP评分可在血液恶性肿瘤合并急性呼吸衰竭患者入院时计算,基于 readily available 变量。
  • 评分的潜在临床获益有待评估。

研究设计与样本

  • 前瞻性多中心队列研究,纳入ICU血液系统恶性肿瘤合并急性呼吸衰竭患者。
  • 推导队列1,092例中134例(12.3%;95%CI 10.4-14.4%)确诊PjP;验证队列238例中15例(6.3%;95%CI 3.6-10.2%)确诊PjP。
  • 模型在独立前瞻性多中心队列中验证,使用30组插补数据集评估性能。

主要发现

  • 模型纳入年龄、淋巴增殖性疾病、抗肺孢子菌预防、呼吸症状出现至ICU入住天数、休克、胸片模式及胸腔积液。
  • 推导队列评分中位数3.5(IQR 1.5-5.0,范围-3.5至8.5);验证队列中位数1.0(IQR 0-2.0,范围-3.5至6.0)。
  • 推导队列平均AUC 0.80(95%CI 0.76-0.84),验证队列平均AUC 0.83(95%CI 0.72-0.93)。
  • 验证队列最佳阈值3时,敏感度86.7%、特异度67.7%,10%患病率下阴性预测值97.9%。
  • 模型校准良好(拟合优度-0.75)。

关键数值与推荐

  • 验证队列最佳阈值定义为3。
  • 阈值3时敏感度86.7%、特异度67.7%,10%患病率下阴性预测值97.9%。
  • 推导队列平均AUC 0.80(95%CI 0.76-0.84),验证队列平均AUC 0.83(95%CI 0.72-0.93)。

临床怎么用

  • 可在入院时计算PjP评分,辅助识别低风险患者。
  • 评分可能有助于早期决策,但其临床获益需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: The incidence of Pneumocystis jirovecii pneumonia (PjP) is rising. Longer time to treatment is associated with higher mortality. OBJECTIVES: To develop a multivariable risk prediction model for PjP diagnosis. METHODS: In a prospective multicenter cohort of ICU patients with hematological malignancies and acute respiratory failure, factors associated with documented PjP were identified. The risk prediction model was tested in an independent prospective multicenter cohort. We assessed discrimination (by areas under the receiver operating characteristic curves [AUCs]) and goodness of fit (by Hosmer-Lemeshow statistics). Model performance was assessed using 30 sets of imputed data sets. MEASUREMENTS AND MAIN RESULTS: Among the 1,330 patients, 134 of 1,092 (12.3%; 95% confidence interval [CI], 10.4-14.4%) had proven PjP in the derivation cohort, as did 15 of 238 (6.3%, 95% CI, 3.6-10.2%) in the validation cohort. The model included age, lymphoproliferative disease, anti-Pneumocystis prophylaxis, the number of days between respiratory symptom onset and ICU admission, shock, chest radiograph pattern, and pleural effusion. The median (interquartile range) score was 3.5 (1.5-5.0) (range, -3.5 to 8.5) in the derivation cohort and 1.0 (0-2.0) (range, -3.5 to 6.0) in the validation cohort. The best threshold was defined on the validation sample as 3, allowing us to reach 86.7% sensitivity and 67.7% specificity for PjP, with a negative predictive value of 97.9% in the case of 10% prevalence. The score had good calibration (goodness of fit, -0.75) and discrimination in the derivation cohort (mean AUC, 0.80; 95% CI, 0.76-0.84) and validation cohort (mean AUC, 0.83; 95% CI, 0.72-0.93). CONCLUSIONS: The PjP score for hematology patients with acute respiratory failure can be computed at admission, based on readily available variables. Potential clinical benefits of using this score deserve assessment.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Azoulay E, Roux A, Vincent F, et al. A Multivariable Prediction Model for Pneumocystis jirovecii Pneumonia in Hematology Patients with Acute Respiratory Failure. Am J Respir Crit Care Med. 2018. PMID: 29995433. doi:10.1164/rccm.201712-2452OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。